Causaly
- Company typePrivate
- Founded2018
- HeadquartersLondon, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
Causaly firmographics
Firmographics- Name
- Causaly
- Legal name
- Causaly Ltd
- Website
- https://causaly.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Causaly industry classification
Industry- Product category
- Life Sciences AI Platform (Drug Discovery & Biomedical Research)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
Keywords
Where Causaly is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Causaly business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Enterprise SaaS Subscription: Causaly operates on a subscription-based model targeting enterprise biopharmaceutical companies. The platform is sold as an enterprise license with annual or multi-year contracts, with pricing based on seat count and feature access. Professional services for implementation and workflow configuration are offered as additional services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise platform with configurable modules and workflow capabilities |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Causaly product offering
Product offeringCore offering
Causaly builds and sells an Agentic AI platform for life sciences R&D that combines a proprietary 500-million-fact biomedical knowledge graph with multi-agent AI orchestration to automate target identification, biomarker discovery, disease pathophysiology analysis, indication expansion, and competitive pipeline intelligence. The platform is sold as enterprise SaaS subscriptions to global biopharmaceutical and biotech organizations and delivers cited, evidence-backed outputs with traceability suitable for FDA regulatory submissions. Additional offerings include the Bio Graph API for programmatic access, professional implementation services, and integrated competitive intelligence through Pipeline Graph.
Product overview
Causaly is an Agentic AI Platform For Life Sciences that provides a unified platform-plus-modules architecture. The core platform consists of an AI workspace with specialized capabilities: the Knowledge Graph (500M facts, 70M directional relationships), Enterprise Data Fabric, and Scientific Information Retrieval System (SIRS). Key products include: Scientific Workflows (end-to-end autonomous AI workflows), Agentic Research (multi-agent AI system with Planner/Executor/Principal Investigator), Discover (AI-powered literature analysis with agentic AI), Bio Graph (biomedical knowledge visualization), Bio Graph API (programmatic access), Pipeline Graph (competitive intelligence for drug pipelines), and Generative AI Copilot (natural language research assistant). The platform is purpose-built for scientific intelligence and execution, enabling target identification, biomarker discovery, disease pathophysiology analysis, and indication expansion across the pharmaceutical R&D pipeline.
Differentiator
Problem solved
Functional benefit
Brands
- Agentic Research: Science-grade AI platform for R&D with multi-autonomous AI agents that plan, research, and synthesize biomedical evidence
- Bio Graph
- Pipeline Graph
- Discover
- Scientific Workflows
- Bio Graph API
- Generative AI Copilot
- Enterprise Data Fabric
- Scientific RAG
Products and services
- Scientific Workflows Solution that converts biopharma research methods into autonomous, repeatable AI workflows run by multi-agent orchestration. Produces structured, evidence-backed, decision-ready outputs including target assessments, indication exploration reports, claims substantiation packages, and safety dossiers. Sold to life sciences R&D organizations.
- Agentic Research Science-grade AI platform for R&D in which domain-specialized AI agents plan, search, reason, and conclude behind a clean chat interface. Multi-agent orchestration coordinates a Planner, Executor, and Principal Investigator to accelerate hypothesis-to-evidence-backed decision workflows. Sold to life sciences R&D organizations.
- Discover AI-powered research application that enables scientists to answer complex biomedical questions faster and more accurately across broader sources. Features automatic generation of detailed reports and integration with external resources such as the Human Protein Atlas. Sold to life sciences R&D teams.
- Bio Graph High-precision biomedical knowledge graph containing 500+ million curated data points and 70 million directional relationships across 8 relationship types. Enables visualization of pathways and mechanisms, uncovers non-obvious hypotheses, and supports prioritization of actionable targets and biomarkers. Sold to life sciences organizations.
- Bio Graph API API offering that enables customers to bring Causaly's life sciences knowledge graph in-house, allowing integration of biomedical knowledge into internal systems and workflows. Sold to enterprises that require programmatic access.
- Pipeline Graph AI-driven competitive intelligence platform for early-stage drug discovery that integrates over 100,000 pipeline drugs, 60,000 research programs, and 15,000 organizations into a dual knowledge graph architecture combined with biological research data. Includes an AI copilot for natural-language queries. Sold to life sciences competitive intelligence teams.
- Generative AI Copilot (Causaly Copilot) The first AI copilot purpose-built for scientists, enabling natural language research queries and AI-powered literature analysis within the Causaly platform. Sold to life sciences research organizations.
- Microsoft Discovery Integration Integrated solution combining Microsoft Discovery's enterprise-scale analytics, prediction, and simulation capabilities with Causaly's knowledge-graph reasoning into a unified workflow for life sciences R&D. Sold to biopharma customers for target identification, biomarker strategy, and in silico prediction.
Quantifiable outcome
- Target prioritization exercises reduced from 4 weeks to 5 days while preserving full traceability
- +5 more outcomes
Companies that use Causaly
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles2 records
Causaly technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability9 records
Feature6 records
Causaly partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, notable and supporting.
- MicrosoftcoreCollaboration announced at Microsoft Build 2026 integrating Microsoft Discovery's enterprise-scale analytics, prediction, and simulation capabilities with Causaly's knowledge-graph reasoning into a unified workflow for life sciences R&D. The combined solution targets biopharma organizations accelerating target identification, biomarker strategy, and in silico prediction while meeting scientific and regulatory standards. Enables R&D teams to move from computational signals to cited, defensible decisions in a governed environment.
- University College London (UCL)notablePartnership to accelerate COVID-19 pandemic research. UCL researchers used Causaly to work on COVID-19 projects including therapeutics development, diagnostic approaches, epidemiological models, mental health strategies, and healthcare system logistics. Causaly provided access to its biomedical literature platform mapping molecular pathways and potential treatment options.
- Copyright Clearance CentersupportingContent partnership for accessing biomedical literature and publications within the Causaly platform.
- WileysupportingContent partnership for accessing scientific publications within the Causaly platform for life sciences research.
- SagesupportingContent partnership for accessing scientific publications within the Causaly platform.
Scale indicators6 records
Recent moves6 records
Expansion highlights2 records
Causaly competitors and assessment
Company assessmentDirect peers
- Insitro: Insitro applies ML to large-scale biological data generated in-house to discover and develop therapeutics. Like Causaly, it targets the intersection of AI and life sciences R&D for top pharma, though Insitro focuses on data-generation plus ML whereas Causaly focuses on biomedical knowledge representation and reasoning.
- Benchling: Benchling is a cloud platform for life sciences R&D, offering lab notebooks, registry, and workflow tools used by top pharma and biotech. Both companies compete for the same biopharma R&D IT wallet, with Causaly differentiating on AI-driven literature/evidence synthesis and Benchling on experimental data capture and lab workflows.
- Exscientia: Exscientia was a pioneer in AI-driven small molecule drug design using active learning and automated synthesis (now merged with Recursion). It overlaps with Causaly as an AI-for-drug-discovery platform serving pharma partners, though its emphasis is generative chemistry and design-make-test cycles.
- Owkin: Owkin is an AI biotech platform that connects federated learning, multimodal patient data, and pharma partnerships to accelerate research and clinical trials. It overlaps with Causaly in using AI to unlock biomedical evidence for pharma R&D and clinical development, with a stronger emphasis on patient data and clinical trials.
- Recursion Pharmaceuticals: Recursion is an AI-native drug discovery company combining its own high-throughput wet-lab data with ML models to build a 'map of biology.' It overlaps with Causaly's mission to use AI for life sciences, with Recursion emphasizing proprietary experimental data and internal pipelines versus Causaly's literature-and-knowledge-graph approach.
- Isomorphic Labs: Alphabet's Isomorphic Labs applies DeepMind's AI to drug discovery, combining protein structure prediction and computational chemistry. It is a deep-pocketed competitor pursuing the same 'AI for life sciences R&D' thesis as Causaly, though more weighted toward structural biology and in silico molecule design.
Broad incumbents
- Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software widely used in pharma drug discovery. It overlaps with Causaly in serving pharma R&D with scientific software, but focuses on molecular simulation and materials science rather than literature/knowledge graph reasoning.
- Palantir Technologies: Palantir's Foundry platform is used by several large pharma and biotech companies for data integration and analytics across R&D and operations. It is a broader data and analytics incumbent that could compete with or complement Causaly's Enterprise Data Fabric layer inside pharma IT environments.
Others
- Clarivate: Clarivate offers scientific intelligence and research databases such as Cortellis and Web of Science, used by pharma for competitive intelligence and drug pipeline analysis. It is thematically adjacent to Causaly's Pipeline Graph and competitive intelligence modules, though it is primarily a data vendor rather than an AI agent platform.
- Elsevier (RELX): Elsevier owns major biomedical literature databases (Embase, Scopus, ScienceDirect) and Reaxys for chemistry, forming the upstream content backbone that life sciences AI platforms including Causaly integrate. It is a key content partner/competitor depending on whether Elsevier expands into AI-driven reasoning on top of its own data.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Causaly social profiles
Digital presenceCausaly compliance and trust
Trust signalCompliance1 record
Causaly financial estimates
Financial estimateRevenue estimate
Valuation estimate
Causaly leadership team
Management profileNumber of profiles
Profiles4 records
Causaly funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Causaly M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Causaly
What does Causaly do?
Causaly builds and sells an Agentic AI platform for life sciences R&D that combines a proprietary 500-million-fact biomedical knowledge graph with multi-agent AI orchestration to automate target identification, biomarker discovery, disease pathophysiology analysis, indication expansion, and competitive pipeline intelligence. The platform is sold as enterprise SaaS subscriptions to global biopharmaceutical and biotech organizations and delivers cited, evidence-backed outputs with traceability suitable for FDA regulatory submissions. Additional offerings include the Bio Graph API for programmatic access, professional implementation services, and integrated competitive intelligence through Pipeline Graph.
Is Causaly a public or private company?
Causaly is a private company. It is classified as venture growth investor backed and is currently operating.
When was Causaly founded?
Causaly was founded in 2018. It employs 101 to 250 people.
Where is Causaly based?
Causaly is headquartered in London, United Kingdom, in the Europe region.
How does Causaly make money?
One revenue line is on record: enterprise SaaS Subscription.
Who are Causaly's main competitors?
Direct peers on record are Insitro, Benchling, Exscientia, Owkin, Recursion Pharmaceuticals and Isomorphic Labs. Broad incumbents are Schrödinger and Palantir Technologies. Others are Clarivate and Elsevier (RELX).
Does Causaly have an API?
Yes. Causaly offers a Bio Graph API that enables users to bring the most powerful life sciences knowledge graph in-house. The API License document is available (Last Updated: December 6, 2023). The platform also supports MCP (Model Context Protocol) frameworks for data integration, as mentioned in the context of agentic AI workflows. Developer documentation is at get.causaly.com/hubfs/Legal/Causlay%20API%20License%20(2023.12.06).pdf.
What industry is Causaly in?
Causaly's product category is Life Sciences AI Platform (Drug Discovery & Biomedical Research). Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 541714 and its SIC code is 8731.